Furthermore, although still not definitive, there is some evidence that GnRH antagonists may have a better CV safety profile than GnRH agonists [11,12,13,14,15], which could lead to a paradigm shift in treatment options, especially as a large proportion of men initiating treatment for prostate cancer have pre-existing CV events or are at high risk for CV events [14,16,17], further demonstrating the unmet need for new GnRH antagonists. The gene discussed is GNRH1; the disease is prostate cancer.